{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_c5_inhibitor",
          "name": "C5 Inhibitor"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_corticosteroids",
          "name": "Corticosteroids"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_plasmapheresis",
          "name": "Plasmapheresis"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_mycophenolate_mofetil",
          "name": "Mycophenolate mofetil"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_tacrolimus",
          "name": "Tacrolimus"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_complement_inhibitors",
          "name": "Complement inhibitors"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_eltrombopag",
          "name": "Eltrombopag"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.69,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.68,
          "safety_risk": 0.2,
          "graph_bonus": 0.12,
          "conflict_penalty": 0.06
        },
        "graph_signals": {
          "support_weight": 1.55,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Eculizumab 通过补体抑制作用于该病"
          ],
          "safety_risk": [
            "Skeptic 指出支持性证据不足以确认长期疗效"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H2",
        "score": 0.67,
        "components": {
          "mechanism_fit": 0.82,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.06
        },
        "graph_signals": {
          "support_weight": 1.45,
          "contradiction_weight": 0.85,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ravulizumab 作为补体抑制剂与Eculizumab相似机制"
          ],
          "safety_risk": [
            "潜在相同风险路线导致治疗效果不确定"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H3",
        "score": 0.64,
        "components": {
          "mechanism_fit": 0.78,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 0.75,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Avacopan 通过调节补体途径作用于该疾病"
          ],
          "safety_risk": [
            "缺乏长时间跟踪效果的研究"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H4",
        "score": 0.63,
        "components": {
          "mechanism_fit": 0.78,
          "class_prior": 0.58,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 0.75,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "C5 Inhibitor直接靶向补体系统"
          ],
          "safety_risk": [
            "可能存在耐药或反跳现象"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H5",
        "score": 0.6,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.55,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.62,
          "safety_risk": 0.2,
          "graph_bonus": 0.08,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 1.0,
          "contradiction_weight": 0.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Corticosteroids常用于控制炎症"
          ],
          "safety_risk": [
            "短期效益可能伴随长期风险"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H6",
        "score": 0.58,
        "components": {
          "mechanism_fit": 0.72,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.6,
          "safety_risk": 0.2,
          "graph_bonus": 0.08,
          "conflict_penalty": 0.06
        },
        "graph_signals": {
          "support_weight": 0.9,
          "contradiction_weight": 0.68,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Plasmapheresis用于清除有害成分"
          ],
          "safety_risk": [
            "疗效依赖于具体疾病表型"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H7",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.55,
          "safety_risk": 0.2,
          "graph_bonus": 0.08,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.6,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Cyclosporine用于免疫调节"
          ],
          "safety_risk": [
            "与常见共病存在潜在冲突"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H8",
        "score": 0.53,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.45,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.52,
          "safety_risk": 0.2,
          "graph_bonus": 0.07,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.55,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Rituximab可能改变疾病过程"
          ],
          "safety_risk": [
            "缺乏针对该病症的全面临床数据"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H9",
        "score": 0.5,
        "components": {
          "mechanism_fit": 0.58,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.06,
          "conflict_penalty": 0.04
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.5,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Mycophenolate mofetil用于控制免疫反应"
          ],
          "safety_risk": [
            "可能导致免疫抑制效果相关风险"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H10",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.55,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.48,
          "safety_risk": 0.2,
          "graph_bonus": 0.06,
          "conflict_penalty": 0.04
        },
        "graph_signals": {
          "support_weight": 0.65,
          "contradiction_weight": 0.45,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Tacrolimus作为免疫抑制剂"
          ],
          "safety_risk": [
            "疗效依赖于剂量和个体反应"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H11",
        "score": 0.45,
        "components": {
          "mechanism_fit": 0.52,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.46,
          "safety_risk": 0.2,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.04
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.45,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Complement inhibitors涉及该疾病"
          ],
          "safety_risk": [
            "机制不明确，治疗链不清晰"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H12",
        "score": 0.4,
        "components": {
          "mechanism_fit": 0.45,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.42,
          "safety_risk": 0.2,
          "graph_bonus": 0.04,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.5,
          "contradiction_weight": 0.4,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Eltrombopag理论上支持相关问题的管理"
          ],
          "safety_risk": [
            "缺乏临床试验数据，疗效待证实"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      }
    ],
    "ranking": [
      "H1",
      "H2",
      "H3",
      "H4",
      "H5",
      "H6",
      "H7",
      "H8",
      "H9",
      "H10",
      "H11",
      "H12"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_c5_inhibitor",
          "type": "Drug",
          "label": "C5 Inhibitor",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_corticosteroids",
          "type": "Drug",
          "label": "Corticosteroids",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_plasmapheresis",
          "type": "Drug",
          "label": "Plasmapheresis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_rituximab",
          "type": "Drug",
          "label": "Rituximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mycophenolate_mofetil",
          "type": "Drug",
          "label": "Mycophenolate mofetil",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tacrolimus",
          "type": "Drug",
          "label": "Tacrolimus",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_complement_inhibitors",
          "type": "Drug",
          "label": "Complement inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_eltrombopag",
          "type": "Drug",
          "label": "Eltrombopag",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_a_h_u_s",
          "type": "Disease",
          "label": "Atypical haemolytic uraemic syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_c5_inhibitor",
          "type": "Drug",
          "label": "C5 Inhibitor",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_corticosteroids",
          "type": "Drug",
          "label": "Corticosteroids",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_plasmapheresis",
          "type": "Drug",
          "label": "Plasmapheresis",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rituximab",
          "type": "Drug",
          "label": "Rituximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_mycophenolate_mofetil",
          "type": "Drug",
          "label": "Mycophenolate mofetil",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_tacrolimus",
          "type": "Drug",
          "label": "Tacrolimus",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_complement_inhibitors",
          "type": "Drug",
          "label": "Complement inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_eltrombopag",
          "type": "Drug",
          "label": "Eltrombopag",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_eculizumab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知炎症及补体抑制作用于此病"
        },
        {
          "source": "drug_ravulizumab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与Eculizumab相似的补体抑制机制"
        },
        {
          "source": "drug_avacopan",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "调节补体途径，针对该疾病的理论基础"
        },
        {
          "source": "drug_c5_inhibitor",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接靶向补体系统"
        },
        {
          "source": "drug_corticosteroids",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "类固醇在控制炎症中常用"
        },
        {
          "source": "drug_plasmapheresis",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "清除血液中的有害成分"
        },
        {
          "source": "drug_cyclosporine",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "在免疫调节中应用"
        },
        {
          "source": "drug_rituximab",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "抗B细胞疗法可影响疾病过程"
        },
        {
          "source": "drug_mycophenolate_mofetil",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "用于控制免疫反应的药物"
        },
        {
          "source": "drug_tacrolimus",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "免疫抑制剂用于慢性病"
        },
        {
          "source": "drug_complement_inhibitors",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "补体抑制剂与疾病相关"
        },
        {
          "source": "drug_eltrombopag",
          "target": "d_a_h_u_s",
          "relation": "acts_on",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "理论上支持输血相关问题的管理"
        },
        {
          "source": "n_eculizumab",
          "target": "H1",
          "relation": "indicates",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "支持性证据不足以确认疗效"
        },
        {
          "source": "n_ravulizumab",
          "target": "H2",
          "relation": "indicates",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "潜在相同风险路线对治疗效果不确定"
        },
        {
          "source": "n_avacopan",
          "target": "H3",
          "relation": "indicates",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "缺乏长时间跟踪效果的研究"
        },
        {
          "source": "n_c5_inhibitor",
          "target": "H4",
          "relation": "indicates",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "可能存在耐药或反跳现象"
        },
        {
          "source": "n_corticosteroids",
          "target": "H5",
          "relation": "indicates",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "短期效益可能伴随长期风险"
        },
        {
          "source": "n_plasmapheresis",
          "target": "H6",
          "relation": "indicates",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "疗效依赖于具体疾病表型"
        },
        {
          "source": "n_cyclosporine",
          "target": "H7",
          "relation": "indicates",
          "weight": 0.6,
          "agent": "Skeptic",
          "rationale": "与常见共病存在潜在冲突"
        },
        {
          "source": "n_rituximab",
          "target": "H8",
          "relation": "indicates",
          "weight": 0.6,
          "agent": "Skeptic",
          "rationale": "缺乏针对该病症的全面临床数据"
        },
        {
          "source": "n_mycophenolate_mofetil",
          "target": "H9",
          "relation": "indicates",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "可能导致免疫抑制效应相关风险"
        },
        {
          "source": "n_tacrolimus",
          "target": "H10",
          "relation": "indicates",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "疗效依赖于剂量和个体反应"
        },
        {
          "source": "n_complement_inhibitors",
          "target": "H11",
          "relation": "indicates",
          "weight": 0.5,
          "agent": "Skeptic",
          "rationale": "机制不明确，治疗链不清晰"
        },
        {
          "source": "n_eltrombopag",
          "target": "H12",
          "relation": "indicates",
          "weight": 0.4,
          "agent": "Skeptic",
          "rationale": "缺乏临床试验数据，疗效待证实"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65
    },
    "heuristic_priors": []
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "score": 0.69,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Eculizumab通过补体抑制作用于aHUS",
          "支持性证据可确认短期疗效"
        ],
        "caveats": [
          "长期疗效尚未确立"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "score": 0.67,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Ravulizumab作为补体抑制剂与Eculizumab具有相似机制"
        ],
        "caveats": [
          "潜在相同风险路线导致治疗效果不确定"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "score": 0.64,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Avacopan通过调节补体途径作用于该疾病"
        ],
        "caveats": [
          "缺乏长期跟踪效果的研究"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Eculizumab与Ravulizumab通过补体抑制途径作用于aHUS",
          "reason": "已知机制与有效性支持"
        }
      ],
      "remaining_gaps": [
        "各假设的长期疗效和安全性数据尚需补充"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": [
        "需优先考虑具有明确机制并有支持性循证的候选药物"
      ]
    },
    "prompt_patches": [],
    "heuristics": []
  }
}